Pamicell Launches New Cell Culture Medium Product

Pamissel announced on the 28th that it will launch a cell culture medium product called ‘Half-Serum™ DMEM’. The new product will be showcased at the Korean Society for Basic Medical Science conference held on the 29th.

Half-Serum™ DMEM, developed using Pamissel’s patented culture medium technology, contains active pharmaceutical ingredients produced by Pamissel’s Biochemical Division. This product features a 50% reduction in FBS usage while maintaining the same culture efficacy as before.

FBS (Fetal Bovine Serum) is an essential component in cell culture media, containing a high concentration of embryonic growth-promoting factors that support cell survival and growth by supplying necessary nutrients and growth factors. However, it is currently fully imported in South Korea and represents the largest cost in the cell culture process, posing an economic burden for domestic bio companies.

A Pamissel representative stated, "Large companies producing antibody drugs culture cells in large bioreactors for protein expression and use hundreds of billions of won worth of FBS annually." He added, "Using Half-Serum™ DMEM can reduce the cost of FBS, which accounts for the majority of cell culture expenses, by half. Companies and research institutes involved in cell research can also achieve significant cost savings."

He emphasized, "The domestic culture medium industry market size is projected to reach 890 billion won by 2027, indicating a continuously growing industry. Half-Serum™ DMEM, developed through the collaboration of Pamissel’s Biomedical and Biochemical Divisions, will lead the domestic cell culture medium market."

This content was produced with the assistance of AI translation services.